Indonesia Issues Emergency Use Authorization for Sinopharm's Covid-19 Vaccine

    Theofilus Ifan Sucipto - 30 April 2021 14:28 WIB
    Indonesia Issues Emergency Use Authorization for Sinopharm's Covid-19 Vaccine
    Illustration (Photo:Medcom.id)



    Jakarta: The Food and Drug Monitoring Agency (BPOM) has issued the Emergency Use Authorization (EUA) for covid-19 vaccine produced by Chinese pharmaceutical company Sinopharm.

    "The BPOM issued the EUA for the Sinopharm covid-19 vaccine on Thursday," BPOM Head Penny Lukito said during a press conference here on Friday.






    According to her, the EUA issuance was based on the evaluation results.

    "The vaccine has met the requirements. The safety aspect of the Sinopharm vaccine is good. The side effects can be tolerated," she explained.

    In a bid to accelerate and expand the coverage of covid-19 vaccination in order to achieve immunity faster, the Government has launched the Gotong Royong Covid-19 Vaccination Program (covid-19 vaccination in mutual cooperation.

    Organized by state-owned enterprises, the program will use covid-19 vaccines from Sinopharm, Gamaleya and CanSino.

    (WAH)

    Bagaimana tanggapan anda mengenai artikel ini?

    Komentar

    LOADING
    Cara untuk mendapatkan Berita terbaru dari kami.

    Ikuti langkah berikut ini untuk mendapatkan notifikasi

    1. Akses Pengaturan/Setting Browser Anda
    2. Akses Notifications pada Pengaturan/Setting Browser Anda
    3. Cari https://m.medcom.id pada List Sites Notifications
    4. Klik Allow pada List Notifications tersebut

    Anda Selesai.

    Powered by Medcom.id